About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

New Spherix Global Insights Data Reveals 85% of FSGS Patients Have Actively Progressing Disease Despite Treatment, Underscoring Urgent Demand for Innovative Treatments

By: via GlobeNewswire

EXTON, PA, June 10, 2025 (GLOBE NEWSWIRE) -- Patients battling focal segmental glomerulosclerosis (FSGS) often face a discouraging path, marked by continued disease progression and limited therapeutic options. For nephrologists, this rare kidney disease is one of the more challenging to manage, with most patients – over 50% – considered to be sub-optimally managed. The latest findings from Spherix Global Insights' annual Patient Chart Dynamix™: FSGS (US) report reveal that nephrologists are closely following the pipeline and eager to adopt new agents once they are approved, especially ones that address the underlying cause of the disease. 

This deep dive into the treatment patterns of 518 non-dialysis FSGS patients under the care of 161 U.S. nephrologists highlights the need for new and targeted therapeutic options. In the absence of any approved agents, physicians are currently forced to rely on supportive care – including SGLT2 inhibitors and RAASi therapies – and systemic corticosteroids, with limited degrees of success in halting disease progression. 

However, there is reason for optimism. As multiple promising agents advance through the pipeline, nephrologists are keeping a close watch and report strong readiness to begin prescribing new agents once approved and available. Familiar names like sparsentan (marketed as Filspari for IgA nephropathy by Travere Therapeutics) and atrasentan (marketed as Vanrafia for IgA nephropathy by Novartis), are viewed as especially promising for the treatment of FSGS. These agents – and others such as Vertex’s inaxaplin, Apellis’ pegcetacoplan, and Dimerix’s DMX-200 following closely behind – represent a new wave of potentially disease-targeted interventions that physicians hope will ultimately help to minimize the need for steroids and other immunosuppressive therapy. 

While physicians are currently unified in their belief that early and more targeted intervention is essential for successful patient outcomes, at present they are left to rely on proteinuria and eGFR levels to guide treatment decisions. When evaluating new therapies, they will ultimately look for strong clinical data and proven effectiveness in reducing proteinuria and slowing the progression of kidney disease. 

Beyond the physician perspective, this report provides an in-depth look at patient types, beginning with referral and diagnosis, including genetic testing and disease classification, as well as demographics and treatment patterns, to allow for the segmentation of target patient types and the ability to uncover specific unmet needs. Notably, while most physicians indicate that they treat APOL-1 positive FSGS patients very differently than those who do not have the genetic marker, fewer than one-half of FSGS patients have been genetically tested. 

As nephrologists look ahead to the arrival of potential new therapies, understanding how nephrologists are currently treating FSGS—and where those strategies fall short—is essential for those developing and delivering innovative new solutions. 

About Patient Chart Dynamix™ 

Patient Chart Dynamix™ is an independent service that includes robust patient chart audits and integrated specialist surveys fielded biannually. This research provides an in-depth, real-world view of treatment practices by combining verified patient data with attitudinal insights from physicians. The series highlights clinical decision-making, treatment sequencing, and outcomes for targeted patient populations across key therapeutic areas. 

About Spherix Global Insights   

Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle.   

The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community.   

As a trusted advisor and industry thought leader, Spherix’s unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth.   

To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn.    

For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: https://clientportal.spherixglobalinsights.com    

Spherix Global Insights Contacts   

Tucker Hurtado, Nephrology Franchise Head  

Tucker.Hurtado@SpherixGlobalInsights.com  

NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight’s analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release.


Tucker Hurtado, Nephrology Franchise Head
Spherix Global Insights
4848794284
tucker.hurtado@spherixglobalinsights.com

More News

View More
3 Healthcare Stocks Using AI to Drive Growth
Via MarketBeat
Topics Artificial Intelligence
Tickers BSX HIMS TEM
Get Exposure to Millennials' Purchasing Power With This ETF
Via MarketBeat
Topics ETFs
Tickers AAPL DASH DIS GOOGL META MILN
Why a $4.5 Billion Smart Debt Move Is Fueling Dell’s AI Ambitions
Via MarketBeat
Topics Artificial Intelligence
Tickers DELL
Beam Global Gets Buy Rating With 101% Upside Potential
Via MarketBeat
Topics Intellectual Property
Tickers BEEM
These 3 Crypto Stocks Could Get a Bump as Dollar Trust Weakens
Via MarketBeat
Topics ETFs Economy World Trade
Tickers BITF COIN HOOD
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.